![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/22/2916275/0/en/Certa-Therapeutics-Receives-EU-Orphan-Designation-for-FT011-a-GPR68-Inhibitor-Being-Developed-as-an-Anti-Fibrotic-Treatment-for-Systemic-Sclerosis.html
https://www.fiercebiotech.com/biotech/brandon-capital-raises-180m-fund-support-australia-new-zealand-biotechs
https://www.globenewswire.com//news-release/2024/02/19/2831083/0/en/Certa-Therapeutics-FT011-Granted-US-FDA-Fast-Track-for-the-Treatment-of-Systemic-Sclerosis.html
https://www.globenewswire.com//news-release/2023/11/15/2781377/0/en/Certa-Therapeutics-presents-positive-data-from-a-Phase-2-clinical-study-highlighting-the-potential-benefit-of-FT011-as-a-novel-treatment-for-scleroderma.html
https://www.prnewswire.com/news-releases/certa-therapeutics-ft011-granted-us-fda-orphan-drug-designation-for-the-treatment-of-systemic-sclerosis-301961921.html
https://endpts.com/australian-biotech-certa-therapeutics-touts-a-positive-mid-stage-data-readout-using-old-shire-drug/
https://www.fiercebiotech.com/biotech/ex-shire-drug-improves-outcomes-autoimmune-disease-setting-certa-path-phase-3